Serious Mental

• President Trump issued an Executive Order directing the Department of Health and Human Services to expedite access to treatments for patients with serious mental illness. • The FDA is accelerating its review process for mental health therapies in response to the directive. • This policy shift aims to reduce barriers to treatment approval and expand therapeutic options for affected patients.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.